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Chemotherapy is a leading intervention against cancer. Albeit highly effective,
chemotherapy has a multitude of deleterious side-effects including skeletal muscle
wasting and fatigue, which considerably reduces patient quality of life and survivability. As
such, a defense against chemotherapy-induced skeletal muscle dysfunction is required.
Here we investigate the effects of oxaliplatin (OXA) treatment in mice on the skeletal
muscle and mitochondria, and the capacity for the Poly ADP-ribose polymerase (PARP)
inhibitor, BGP-15, to ameliorate any pathological side-effects induced by OXA. To do
so, we investigated the effects of 2 weeks of OXA (3 mg/kg) treatment with and without
BGP-15 (15 mg/kg). OXA induced a 15% (p< 0.05) reduction in lean tissue mass without
significant changes in food consumption or energy expenditure. OXA treatment also
altered the muscle architecture, increasing collagen deposition, neutral lipid and Ca2+
accumulation; all of which were ameliorated with BGP-15 adjunct therapy. Here, we are
the first to show that OXA penetrates the mitochondria, and, as a possible consequence
of this, increases mtROS production. These data correspond with reduced diameter
of isolated FDB fibers and shift in the fiber size distribution frequency of TA to the left.
There was a tendency for reduction in intramuscular protein content, albeit apparently not
via Murf1 (atrophy)- or p62 (autophagy)- dependent pathways. BGP-15 adjunct therapy
protected against increased ROS production and improved mitochondrial viability 4-fold
and preserved fiber diameter and number. Our study highlights BGP-15 as a potential
adjunct therapy to address chemotherapy-induced skeletal muscle and mitochondrial
pathology.
Keywords: skeletal muscle, oxaliplatin chemotherapy, BGP-15, mitochondria, protein synthesis, muscle wasting,
mitochondrial reactive oxygen species
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INTRODUCTION
Cancer is a leading cause of world-wide mortality accounting
for 8.2 million deaths in 2012 alone, with this figure predicted
to reach 14 million by 2034 (World Health Organisation, 2015).
In the majority of cases, first line treatment involves systemic
chemotherapy administration. Chemotherapeutic agents target
the molecular characteristics of cancerous cells, such as rapid
replication, to chemically-induce cell death (de Gramont et al.,
2000; Sorensen et al., 2016). However, due to its non-specific
and systemic mode of action, chemotherapy also elicits effects
on healthy tissues causing the classic side-effects attributable to
anti-cancer therapy including nausea, vomiting, cardio-toxicity,
immune disorders, peripheral and axial neuropathy, hair and
weight loss and debilitative fatigue (Greene et al., 1993; Zitvogel
et al., 2008; Gilliam and St Clair, 2011; National Cancer
Institute, 2012; Ariaans et al., 2015). These side-effects often
limit treatment tolerability, efficacy and therapeutic options,
sometimes leading to the cessation of treatment all together
and ultimately reducing patient quality of life and prognosis
due to the development of co-morbidities (Gilliam and St
Clair, 2011; Scheede-Bergdahl and Jagoe, 2013; Argilés et al.,
2015; Cheregi et al., 2015). Emerging evidence suggests that
the skeletal muscle is also a target of chemotherapy-induced
atrophy (Pfeiffer et al., 1997), weakness and fatigue (Gilliam
and St Clair, 2011), dysfunction (Scheede-Bergdahl and Jagoe,
2013; Bredahl et al., 2016) and insulin resistance (Ariaans
et al., 2015). These effects appear to be more pronounced
when chemotherapy is administered in childhood, due to the
hyperplastic and hypertrophic nature of skeletal muscle at this
early stage of life and persist well into adulthood (Ness et al.,
2007; Scheede-Bergdahl and Jagoe, 2013; Ariaans et al., 2015).
Since skeletal muscle has a high energy requirement, and thus a
high mitochondrial density, emerging data suggests that skeletal
muscle pathology may be underpinned by damage induced to
the mitochondrial by chemotherapy administration (Davies and
Doroshow, 1986; Doroshow and Davies, 1986; Sarosiek et al.,
2013; Tabassum et al., 2015).
Oxaliplatin (OXA), a platinum (Pt)-based alkylating agent,
is the leading anti-neoplastic agent against colorectal cancer
(André et al., 2004; Gourdier et al., 2004; Aschele et al.,
2005; Alcindor and Beauger, 2011), neuroblastoma (Tran
et al., 2015) and solid tumors (Mascarenhas et al., 2013).
Primarily, OXA elicits its antineoplastic effect by intercalating
Pt adducts into the nuclear DNA (nDNA) causing single-
stranded damage, cell cycle arrest and apoptosis (Alcindor and
Beauger, 2011). In addition, it has been demonstrated that OXA
has the capacity to induce a mitochondrially-driven apoptotic
response that is independent of nDNA damage (Gourdier
et al., 2004), implicating the mitochondria as inadvertent
targets of OXA treatment. Preliminary findings by our
laboratory demonstrate that OXA treatment induces significant
mitochondrial dysfunction involving elevated mitochondrial
(mt) reactive oxygen species (ROS) production and reduced
viability of the mitochondrial pool in vitro (Cheregi et al., 2015).
As hypothesized by us previously, these findings suggest that
OXA explicitly damages the nDNA, but inadvertently hinders the
mitochondria as well, by eliciting damage to either functional
proteins, the mtDNA, or both (Sorensen et al., 2016). It has
been established that an imbalance in the oxidant/antioxidant
ratio stimulates atrophy pathways, impedes skeletal muscle
growth and/or muscle turnover supressing the capacity to repair
chemotherapy-induced damage (as reviewed in Sorensen et al.,
2016). The net effect on the skeletal musculature would be
wasting and a detrimental loss of force production capacity.
While this has been increasingly established for the anthracycline
chemotherapeutic, doxorubicin, which is a known pro-oxidant
(Davies and Doroshow, 1986; Doroshow and Davies, 1986; Jones,
2006; Ashley and Poulton, 2009; Gilliam et al., 2012, 2013),
and more recently established for combination colorectal cancer
chemotherapy treatment regimens which include oxaliplatin (i.e.,
FOLFOX André et al., 2004; Aschele et al., 2005), there is
currently no data describing the effects of OXA on the skeletal
muscular system.
Here we investigate the experimental therapeutic BGP-
15 (O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime),
which has previously been used in clinical trials for the
treatment of skeletal muscle pathology associated with Type 2
Diabetes (through insulin sensitization; U.S. National Institutes
of Health, 2014), Duchenne Muscular Dystrophy (DMD)
and heart failure (through anti-inflammatory and anti-fibrotic
mechanisms; Gehrig et al., 2012; Sapra et al., 2014). Via its
action as a modulator of the cytoprotective response to cellular
stress, and specifically as a poly (ADP-ribose) polymerase
(PARP) inhibitor, heat shock protein-inducer (Sarszegi et al.,
2012; U.S. National Institutes of Health, 2014), membrane lipid
therapeutic (Salah et al., 2016) and an antioxidant inducer
(Henstridge et al., 2014), BGP-15 has previously been shown
to protect against skeletal muscle dysfunction, damage and
wasting (Sapra et al., 2014; Kennedy et al., 2016; Salah et al.,
2016). As such, it is of particular interest to us for protection
against chemotherapy-induced skeletal muscle dysfunction due
to its capacity to improve myopathic structural changes. Thus,
we aimed to (1) investigate the effects of OXA treatment
on skeletal muscle and mitochondrial function at the whole
body, myocellular, and molecular level; and (2) evaluate the
efficacy of BGP-15 co-treatment as a therapeutic avenue through
which to protect the skeletal muscle during chemotherapy
treatment. We hypothesized that OXA treatment would (1)
induce skeletal muscle atrophy, wasting and/or pathology and (2)
penetrate the mitochondria to induce mitochondrial pathology
and dysfunction; and that (3) BGP-15 would preserve the
skeletal muscle mass, as well as protect against OXA-induced
perturbations in muscle morphology and mitochondrial health,
thus reducing the impact of chemotherapy treatment on the
skeletal muscular system.
MATERIALS AND METHODS
Ethics Approval
All experimental procedures were approved by the Victoria
University Animal Ethics Experimentation Committee and
conformed to the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.
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Animals
Six-week old male Balb/C mice were obtained from the
Australian Resource Centre (Western Australia, Australia) and
were acclimatized for a minimum of 3 days before being
randomly assigned to treatment groups (n = 8). Mice were
housed in groups of 4–5 and maintained on a 12 h light/dark
cycle with ad-libitum access to standard rodent chow and water.
Prior to treatment (on day 1), mice were scanned for body
composition. Mice were then treated with either vehicle (0.1%
DMSO; VEH), OXA (3 mg/kg; Sigma Aldrich, Australia) or
OXA with BGP-15 (15 mg/kg, kindly donated by N-gene R&D,
Australia; OXAB) via intraperitoneal injection on days 1, 3,
5, 8, 10, and 12. The cumulative OXA dosage used in our
study is equivalent to that given to humans, scaled for the
metabolic activity of mice according to Reagan-Shaw et al.
(2008). The concentrations and injection protocol for OXA
have been used and published by our collaborators previously
(Stojanovska et al., 2015; McQuade et al., 2016b), while the BGP-
15 dosage administered has proven efficacious against murine
myopathies (Chung et al., 2008; Gehrig et al., 2012; Kennedy
et al., 2016). On day 14, mice were housed in the Promethion
metabolic system for 24 h and on day 15, scanned again for
changes in body composition, prior to being anaesthetized
(sodium pentobarbitone, 60 mg/kg). When no reflexes were
present, muscles and organs were harvested. Food and water
consumption was monitored on treatment days.
Body Composition Analysis
Directly prior to the first treatment on Day 1 and prior to
non-recovery surgery on Day 15, mice were analyzed for body
composition (lean, fat and water mass) using an echo magnetic
resonance imaging (echoMRI) body composition analyser (EMR-
150, Echo Medical Systems, USA). Scans were conducted in
triplicate at each time point and included both the standard
and water phases of analysis, with a 30-s time-lapse between
each scan. Data is presented as the mean of the three scans.
Composition results are expressed as an index against body
weight (measure/body weight) with pre-treatment data not
shown since no significant differences between groups were
observed.
Metabolism, Voluntary Exercise Capacity,
and Behavioral Analysis
Mice were housed individually in a Promethion metabolic cage
system (Sable Systems, USA) for 24 h after the cessation (day
14–15) of treatment. Respiratory gases were measured with an
integrated fuel cell oxygen (O2) analyser, spectrophotometric
carbon dioxide (CO2) analyser and capacitive water vapor partial
pressure analyser (GA3, Sable Systems, USA). Gas sampling
was recorded at 1 s intervals with water vapor, pressure and
temperature controlled for, to assess indirect calorimetry. Gas
sensors were calibrated weekly with 100% N2 (zero reference
for all other gas and vapor) and a span gas with known
concentrations of O2 and CO2. The Promethion system utilizes
a pull-mode, negative pressure system, through a multi-channel
mass flow generator which measures and controls airflow
(FR8, Sable Systems, USA) at an incurrent flow rate of 2,000
mL/min. Respiratory quotients (RQ) were calculated as a
ratio of CO2 production to O2 consumption with energy
expenditure calculated using the Weir equation: Kcal/hr =
60∗(0.003941∗VO2 + 0.001106
∗VCO2) (Kaiyala et al., 2012).
Mouse ambulatory activity and position (x, y, and z axis, 0.25
cm spacing) within the cages was recorded continuously (BXYZ-
R Sable Systems, USA). Mice also had free access to running
wheels with revolutions recorded using a magnetic reed switch.
Mice were permitted ad libitum access to food and water
hoppers which were suspended from load cells to continuously
record interaction with food and water, as well as consumption.
Measures of time spent during behavioral activities were derived
from the ethoSCAN behavioral macro supplied by Sable Systems
(USA), with short lounges identified as periods of inactivity
<60s and long lounges >60s. Time spent on particular activities
were calculated as a percentage of total time spent in the cage
(total 24 h).
Histology
Following excision of tibialis anterior (TA) from mice, muscles
were coated in OCT compound and snap frozen in liquid
nitrogen-chilled isopentane (Sigma Aldrich, Australia). Frozen
OCT embedded TAmuscles were cryosectioned (10µm), stained
and mounted according to specific protocols as described below.
Images of the whole section were captured using a Zeiss
Axio Imager Z2 microscope (Carl Zeiss MicroImaging GmbH,
Germany) at 10x magnification and a further magnification of
200x was used for greater detailed images.
Haematoxylin & Eosin (H&E)
Slides were stained using a standard H&E staining protocol
(30 s incubation in haematoxylin and 1m 45 s incubation in
eosin; Timpani et al., 2016) and mounted with DPx (BDH,
Poole, UK). To determine fiber size frequency distributions, 200
fibers per section (except for those on the periphery that were
cropped) were individually circled on three images taken from
the top, middle and bottom along the midline from each TA cross
section. ImageJ (NIH, USA) measurement analysis was used for
measurement data. Since the TA has been shown to localize
different fiber types to different areas of the muscle this approach
was used to limit the influence of fiber type variations within the
muscle cross section (Wang and Kernell, 2001; Shortreed et al.,
2009).
Oil Red O (ORO)
Air dried TA sections were fixed in 3.7% formaldehyde for 60m
before being rinsed in x3 individual deionized water baths for 30 s
each. Samples were then incubated in Oil RedOworking solution
[5:1 Oil Red O (Sigma Aldrich, Australia) in 60% triethyl-
phosphate (w/v)] for 30 min. Thereafter, samples were washed
three times in individual deionized water baths for 30 s each, then
rinsed in running tap water for 10m before being mounted with
10% glycerol in PBS. Images were converted to 8bit photos and
thresholded, then analyzed by assessing the intensity of black to
white. The full cross section of the TA was imaged and data is
expressed as the Oil Red O positive area (black) as a percentage
of the total cross sectional area (black+ white).
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Alizarin Red
The Ca2+ content of TA sections was assessed using Alizarin
Red (TMS-008-C, Merck Millipore), a dye which chelates with
calcium to form Alizarin Red S-Ca2+ complexes. Slides were
stained for 2m with Alizarin Red, dipped in 100% acetone 20
times, then dipped in 1:1 acetone-xylene 20 times, before being
washed in 100% xylene for 1 m. Samples were mounted with
DPx then the whole cross section of the TA was photographed.
Images were converted to 8bit photos then analyzed by assessing
the intensity of black of the total cross-sectional area. Data is
expressed as arbitrary units.
Gomori Trichrome
Gomori Trichrome (LG) stain (HT10316, Sigma Aldrich,
Australia) distinguishes three muscle components: (1) muscle
(red/pink), (2) nuclei (blue/black) ,and (3) collagen (green-blue).
To achieve this stain, samples were bathed in hematoxylin for
1m before being washed in tap water until the water ran clear.
Samples were then stained with Gomori trichrome for 30 s and
dipped in tap water 20–25 times before being dipped in a 0.2%
acetic acid bath 20 times, then bathed in 0.2% acetic acid for
30 s. Samples were then bathed for 30 s increments in x4 baths
containing 95% (x2) and 100% (x2) ethanol, before being bathed
in xylene for 1 m. Thereafter, samples were mounted with DPx.
The intensity of red (muscle), blue (nuclei) and green (collagen)
pixels were assessed using ImageJ. The full cross section of the TA
was imaged and data is expressed as the percentage of collagen
(green) within the total cross sectional area.
Succinate Dehydrogenase (SDH)
SDH is an enzyme located in the mitochondria that oxidizes
succinate to fumarate. This reaction, in the presence of nitro blue
tetrazolium, is demonstrated by the formation of a blue-purple
product with more intensely colored fibers indicating highly
oxidative fibers with a greater mitochondrial density. Slides
were incubated in working solution (0.2M sodium succinate,
0.2M PBS, 0.05% nitro blue tetrazolium, pH 7.6) for 60 min
at 37◦C, fixed in formal saline (0.9% NaCl, 10% formaldehyde)
and mounted with glycerol jelly. Images were converted to
8bit, thresholded and SDH intensity was measured in full cross
sections of the TA.
Platinum Detection in Subcellular Fractions
Subcellular Fractionation
TA muscles were homogenized in buffer (containing: 100 mM
potassium chloride, 50 mM tris (hydroxymethyl)aminomethane,
5 mM magnesium chloride hexahydrate, 1.8 mM adenosine
triphosphate, 0.5 mM ethylenediaminetetraacetic acid; pH
7.2). Tissue homogenates were transferred to Eppendorf
tubes and centrifuged at 650G for 3 min at 4◦C. The
supernatant, which contains the mitochondria, was decanted
into separate Eppendorf tubes. The pellet which contains
the nuclear fraction was resuspended in RIPA lysis buffer
(25mM tris(hydroxymethyl)aminomethane hydrochloride, 150
mM sodium chloride, 1% sodium deoxycholate and 0.1% sodium
dodecyl sulfate; pH 7.6) and further diluted to a total volume of 4
mL inMilliQwater. Themitochondrial sample was centrifuged at
15,000G for 3 min at 4◦C. The supernatant was discarded and the
mitochondrial pellet was resuspended in 4 mL of MilliQ water.
Atomic Absorption Spectrophotometry
Once the nuclear and mitochondrial fractions were derived,
samples were aspirated into a Shimadzu AA-6300 Atomic
Absorption Spectrophotometer (AAS). The specific AAS
conditions used to carry out these analyses included an air-
acetylene flame, with a fuel flow of 1.5 L/min and an air flow of 15
L/min. The burner height was optimized for each element. Due
to the analytical wavelength used (265.9 nm for Pt), background
correction was required—this was supplied by a D2 lamp using
a slit width of 0.7 nm and a current of 25 mA (Pt). Samples were
aspirated, with three repeat measurements recorded following an
initial 2 s pre-spray time. Individual measurements were taken by
averaging the absorbance readings over 3 s, which also allowed
the calculation of a relative mean square percentage (RMS%)
uncertainty. These three measurements were then averaged
to give a final absorbance reading for each sample. Standard
calibration curves were also produced before each daily run of
samples, with concentration ranges of 10-40 ppm Pt utilized.
Concentration values for the unknown samples were calculated
automatically by the Shimadzu AAWizard software.
Mitochondrial Viability and mtROS
Isolation of Flexor Digitorum Brevis (FDB) Fibers
FDB fibers were isolated according to procedures described by
Schuh et al. (2012). Following surgical excision of the FDB from
both feet, the muscles were incubated in 1 mL of pre-warmed
dissociation media (DMEM, Gibco 10566016; 4.5 mg/ml glucose,
2% FBS, Bovogen Biologicals; 4 mg/mL collagenase A, Roche
10103586001; 50µg/mL gentamycin, Sigma Aldrich, Australia
G1397) for 1 h 45 min (37◦C, 5% CO2). Following the incubation
period, FDB muscles were removed from collagenase and placed
into∼1.5 mL of incubationmedia [DMEM containing 4.5 mg/ml
glucose, no phenol red (Gibco), 2.0% FBS, 0.1% Gentamycin
solution (Sigma Aldrich, Australia G1397)] and triturated with
pipette tips of decreasing bore size to yield isolated fibers. Fibers
were then plated according to analysis methods described below.
Determination of Mitochondrial Viability
Mitochondrial viability was assessed using the fluorescent probes
MitoTracker Green and Red (Molecular Probes, Australia).
MitoTracker Green is a non-selective mitochondrial dye that
labels all mitochondria irrespective of the mitochondrial
membrane potential, while MitoTracker Red only permeates
the mitochondrial matrix and fluoresces in the presence of an
inner mitochondrial membrane potential (19). Mitochondrial
viability was calculated as the percentage ratio of active
mitochondria (MitoTracker Red) to the total mitochondrial pool
(MitoTracker Green).
Fifty microliters of isolated FDB fibers suspended in
incubation media [DMEM containing 4.5 mg/ml glucose, no
phenol red (Gibco), 2.0% FBS, 0.1% Gentamycin solution (Sigma
Aldrich, Australia G1397)] was plated onto matrigel (Sigma
Aldrich, Australia, E1270) coated 96 well microplates (all samples
were run in triplicate) and confluency was determined using a
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light microscope. If ∼60% of the well bottoms was not covered
by isolated FDB fibers, an additional 50µL aliquot of fibers
was dispensed into the well. For wells that did not receive the
additional 50µL of fibers, 50µL of incubation media was added
and the microplate was incubated overnight.
Ten minutes prior to the addition of the MitoTracker dyes,
FCCP and antimycin A (final concentration of 3µM each,
Sigma Aldrich, Australia) were added to the positive control
wells. As FCCP induces the collapse of the mitochondrial
membrane potential and antimycin A inhibits complex III
function, mitochondrial viability decreases as evidenced by a
reduction in the intensity of MitoTracker Red fluorescence.
Following this, a cocktail of MitoTracker Green and Red (final
concentration of 200 and 50 nM, respectively. Molecular Probes)
in Flurobrite media (50µL total, ThermoFisher, Australia) was
added to each well and incubated at 37◦C for 3 min. Fibers
were then washed twice with Flurobrite media and imaged on
anOlympus Inverted FluorescenceMicroscope (IX-81, Olympus,
Tokyo, Japan) using FITC and TRITC filters and a standardized
exposure time. Three random images were taken of each well in
a blinded fashion and with standardized exposure and brightness
settings, and the average intensity of red and green fluorescence
of each image analyzed using ImageJ. Relative MitoTracker
Red fluorescence as a proportion of relative MitoTracker Green
fluorescence was calculated to give a value of mitochondrial
viability percentage. The RFUMitoTracker Green stain were also
expressed as arbitrary units of mitochondrial density/population.
Analyzed images were all taken using standardized imaging
settings, such as ISO and exposure times.
Determination of Mitochondrial Superoxide
Production
Isolated fibers suspended in incubation media were prepared
as mentioned in the previous section. Fibers were labeled with
MitoSOX Red mitochondrial superoxide indicator (Molecular
Probes) to detect superoxide production. MitoSOX reagent stock
solution (5 mM) was diluted in a HBSS/Ca/Mg buffer (10 mM
HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8
mM CaCl2, pH 7.4) at 37
◦C and added to the fibers. Fibers
were incubated at 37◦C in 5% CO2 for 3 min. Following
this the staining solution was removed and, as a counterstain,
cells were labeled with MitoTracker Green for 30 min. After
counterstaining, cells were washed twice with incubation media
and live cells were photographed using an IX-81 Olympus
Inverted Fluorescence Microscope. Images were quantified using
ImageJ software. Data is expressed as MitoSOX Red RFU relative
to the total mitochondrial pool (MitoTracker Green RFU). Three
images were taken of each well in a blinded fashion and the
average intensity of red and green fluorescence of each image
was analyzed using ImageJ. Analyzed images were all taken using
standardized imaging settings, such as ISO and exposure times.
Muscle Protein Extraction and Western
Blotting
Frozen TA muscles were mechanically disrupted (TissueLyser,
Qiagen, Germany) for 30 s at 30 Hz in homogenizing buffer
(0.125 M Tris-HCl, 4% SDS, 10% Glycerol, 10 mM EGTA, 0.1
M DTT) containing 0.1µL.mL−1 of protease and phosphatase
inhibitor cocktail (Sigma Aldrich, Australia), and vortexed,
followed by a freeze-thaw cycle. Protein concentration was
then determined using a commercially available assay (Red
660, G-Biosciences, Astral Scientific, Gymea, Australia), and
samples were diluted to equivalent concentrations (1µg.µL−1)
in homogenizing buffer. Bromophenol blue (1% v/v) was
then added before heating to 95◦C for 5 min. Samples were
loaded into pre-cast 26 well stain-free 8–16% gradient gels
(CriterionTM TGX Stain-FreeTM Precast, BioRad, Gladesville,
Australia) at a concentration of ∼8µg protein per lane with all
constituents present (i.e., no centrifugation). Molecular weight
marker (PageRuler R© Plus, Thermo Scientific, Australia) was
loaded, along with five lanes of increasing volume of a pooled-
sample to generate five-point calibration standard curves on each
gel. This was used for quantification of sample blot intensities
relative to the standard curve both within and between gels,
and ensures sample blot intensities are within the linear range
of the signal (i.e., primary antibody binding is not saturated;
Murphy and Lamb, 2013). After separation by SDS PAGE, stain-
free gels were activated by UV light (ChemiDocTM MP, BioRad,
Gladesville NSW, Australia) and imaged to visualize the total
protein of each lane before the proteins were transferred to PVDF
membranes (Trans-Blot R© TurboTM, BioRad, Gladesville NSW,
Australia). Membranes were then blocked in 20 mM Tris, 150
mM NaCl, and 0.1% Tween 20 (TBST) containing 5% w/v non-
fat milk powder for 1 h at room temperature, then washed in
TBST. After this, membranes were incubated overnight at 4◦C
with rocking, using the following primary antibodies diluted
1:1,000 in TBST containing 5% w/v BSA and 0.1% w/v sodium
azide. Probes used: Bax total (CST #2772), MuRF1 total (ECM
#MP3401), PAR total (Enzo #ALX-804-220), PARP-1 total (Santa
Cruz SC-8007), PARP-2 total (Santa Cruz SC-393310), p70S6K
total (CST #2708), rp-S6 total (C ST #2217), SQSTM1/p62 total
(CST #5114). Membranes were subsequently washed with TBST,
then probed with appropriate horseradish peroxidase-conjugated
secondary antibody (PerkinElmer, Australia) diluted 1:50,000 in
5% non-fat milk TBST for 1 h at room temperature. Protein-
antibody-HRP conjugates were visualized using super sensitive
ECL detection (SuperSignal R© West Femto, Thermo Scientific,
Australia), imaged (ChemiDocTM MP, BioRad, Australia), then
analyzed using software (ImageLab v5.1, BioRad, Australia).
Total protein loading was determined from stain-free gel images
to measure intensity of each lane, which was expressed relative to
the linear regression of the standard curve (Ashley and Poulton,
2009). These values were then used as a loading control to
normalize all blot values for proteins of interest. The proteins
selected were done so to cover a broad spectrum of cellular
degradation pathways, including atrophy, autophagy, protein
synthesis, to preliminarily investigate how OXA induces lean
muscle mass loss. Further, PARP was assessed due to BGP-15’s
inhibitory effect on PARylation.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 7
software using one-way analysis of variance to detect treatment
effects and Tukey post hoc tests for multiple group comparison.
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An α value of 0.05 was considered statistically significant. Data is
presented as means± SEM.
RESULTS
Body Weight and Food Consumption
Reduced food consumption due to gastrointestinal side-effects
(McQuade et al., 2016b) and nausea (Love et al., 1989; Greene
et al., 1993) is associated with chemotherapy treatment in
humans, and as such, body weight and food and water intake
were monitored. From days 1 through 8 of treatment, there
were no significant differences in body weight gain observed
between groups (p > 0.05, Figure 1A), however, weight gain in
OXA and OXAB treated mice plateaued at day 8 and remained
significantly lower than VEH from D10 onwards (p < 0.005;
Figure 1A). There were no significant differences between the
groups in food (Figure 1B) or water (Figure 1C) consumption
over the treatment period (p> 0.05).
BGP-15 Protects against OXA
Induced-Lean and Fat Mass Loss but
Increases Heart/Body Weight Ratio
The effects of OXA treatment on body composition, and the
capacity for BGP-15 to protect against the loss of lean tissue was
investigated in mice using MRI. OXA treatment induced a 15%
reduction in the lean mass index (p < 0.05; Figure 2A) with
this loss being completely protected against via adjunct treatment
with BGP-15 (p < 0.05). The loss of lean tissue observed was not
associated with changes in hydration status (p> 0.05, Figure 2C),
however there was a trend for OXA treatment to reduce the
fat mass index by 15% (p = 0.075; Figure 2B) with BGP-15
treatment affording no protection against this measure (p> 0.05,
Figure 2B).
The wet weight of individual hind limb skeletal muscles,
organs and the diaphragm was measured immediately after
excision. There were no significant changes in wet tissue weights
between treatment groups, with the exception of the liver which
was reduced by 5% following OXA treatment (p < 0.05 from
VEH, Figure 2E) and a further 5% following OXAB treatment
(p< 0.0001 from VEH, Figure 2E). Although, there was no effect
of treatments on the absolute heart weight, increased heart size
when normalized to body weight was observed between OXAB
and vehicle (p < 0.005, Figure 2D), however, no significant
differences were observed for other collected muscles and organs
when indexed against body weight.
Metabolic and Exercise Capacity Is
Unaffected by OXA Treatment
To assess the impact of the effects of OXA on the skeletal
muscular system at the whole body level, the metabolism,
voluntary exercise capacity and participation in activities of
daily living (behavioral time budgets) of mice were quantified
in Promethion Metabolic cages (Sable Systems, U.S) for
24 h following the conclusion of the treatment regimen.
Interestingly, no changes were noted in energy substrate
utilization (Figure 3A), overall energy expenditure (Figure 3B),
overall O2 consumption (Figure 3C) or in exercise capacity
(Figures 3D–F), following OXA treatment. Of note however,
OXAB treatment reduced the basal energy expenditure at rest
(p < 0.05, Figure 3B) and had a tendency (p = 0.088) to
reduce the overall time spent on the running wheel, albeit
the same distance was covered when compared to other
groups. Furthermore, OXA treatment significantly reduced
the time spent in inactivity periods longer that 60 s (long
lounges), suggesting that mice were spending less time resting
(Figures 3D,F). Interestingly though, OXA treated mice spent
more time interacting with the food hoppers as seen in
Figure 3D.
OXA Treatment Changes the Fiber
Distribution of TA Sections and Reduces
Isolated FDB Fiber Diameter
With previous studies showing that the oxidative stress induced
by some chemotherapeutic agents potentiates skeletal muscle
FIGURE 1 | Body weight and food consumption over the treatment period. OXA significantly reduced final post treatment body weights, with weight loss
plateauing from D8 of OXA treatment (A). Body weight of OXA treated mice (including OXAB) was significantly reduced from VEH from D10 onwards. No differences
were detected in (B) Food consumption or (C)Water consumption between the groups. D#, treatment day number; Significance, †p < 0.005 OXA and OXAB different
from VEH. n = 6–8.
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FIGURE 2 | BGP-15 protects against Oxaliplatin-induced lean tissue but not fat mass loss. (A) BGP-15 protected against the OXA-induced reduction in LMI.
(B) FMI was reduced by OXA treatment by 15% with no protection afforded by BGP-15. (C) Hydration Index calculated by [(echo derived total water – echo derived
free water)/echo derived lean mass]. (D) Heart weight indexed against body weight showed OXAB treatment significantly increased heart size in relation to body
weight. (E) Absolute wet tissue weights showed no significant difference either as raw or indexed against body weight, however OXA treatment reduced liver size with
adjunct BGP-15 therapy further exacerbating this reduction (Table significance: A = p < 0.05 OXA to VEH. B = p < 0.05 OXA to OXAB. C = p < 0.0001 OXAB to
VEH). BW, Body weight; EDL, Extensor Digitorum Longus; TID. ANT, Tibialis Anterior. Significance: *p<0.05, **p<0.005; Trend: #p = 0.076. n = 6–8.
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FIGURE 3 | BGP-15 reduces basal energy expenditure with OXA treatment not affecting exercise capacity. (A) There was no significant effect of treatment
on the respiratory quotient. (B) Energy expenditure at rest was reduced by BGP-15 adjunct therapy. (C) Oxygen consumption was not effected by treatment.
(D,F) Time budgets of activities of daily living: OXA treatment reduced time spent engaged in long lounges (p < 0.05) while OXAB treatment reduced the time spent
engaged in voluntary wheel running. (E) There was no effect of treatment on total meters covered (combination of wheel and pedestrian meters). CHO, Carbohydrate;
VO2, Volume Oxygen. Table significance: (A) p < 0.05 OXA vs. VEH, (B) p < 0.05 OXA vs. OXAB, (C) trend (p = 0.088) OXA vs. OXAB, (D) trend (p = 0.057) OXA vs.
VEH. Significance: *p < 0.05. n = 6–8.
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dysfunction and atrophy (Bonifati et al., 2000; Gilliam et al.,
2009), we were interested in assessing whether OXA could induce
similar effects at the fiber level. OXA treatment increased the
frequency of small TA fibers by 68% in the 600–899µm bin
range (p < 0.05), whilst reducing fiber frequency within the
1,500–1,799µm bin range (p < 0.005). BGP-15 adjunct therapy
offered protection exclusively against the OXA-induced fiber
frequency reduction in the 1,500–1,799µm range (Figure 4B).
Myopathological analysis of H&E stained TA sections revealed
no ultrastructural changes in nuclei location from the fiber
periphery (normal) to the fiber center (pathological) and no signs
of inflammatory infiltrate, which would both be indicative of
damage and repair pathway activation (Figure 4A). In isolated
FDB fibers, OXA treatment induced a 25% reduction in FDB
fiber diameter (p< 0.0001 from VEH; Figure 8F). This effect was
completely protected against by OXAB treatment (p < 0.0005
from OXA), whereby fiber diameter was comparable to VEH.
BGP-15 Protects against OXA-Induced
Accumulation of Intracellular Ca2+, Fat and
Collagen in TA Muscle
Since intracellular Ca2+ dysregulation and accumulation is
strongly linked with skeletal muscle pathology (Powers et al.,
2007), we assessed the effect of OXA treatment on the
Ca2+ content of TA using Alzarin Red staining (Figure 5A).
OXA treatment increased the intracellular Ca2+ content by
22% from VEH (p < 0.05). This increase in Ca2+ however,
could not be localized to a specific intracellular region (a
limitation of the method) and did not appear to be at a
concentration high enough to activate calpain-mediated damage
responses as centralized nuclei were not observed in H&E
stains (Figure 4A). Since fibrotic connective tissue and fat
infiltration are also features of myopathy (Scheede-Bergdahl and
Jagoe, 2013; Bredahl et al., 2016), Gomori trichrome and ORO
staining were used to assess these markers, respectively. OXA
treatment increased collagen deposition within TA sections by
36% (p < 0.0005, Figure 5B) and induced a 164% increase
in the cross-sectional TA area infiltrated with neutral lipids
(p < 0.05; Figure 5C). All OXA-induced histopathological
features were completely protected against by OXAB treatment
(Figures 5A–C).
Mitochondrial Pt Accumulation and
Increased SDH following OXA Treatment
To establish whether OXA could (a) penetrate the skeletal muscle
and (b) penetrate the double membrane of the mitochondria;
analysis of the skeletal muscle nuclear andmitochondrial fraction
was performed. We have previously hypothesized that OXA
accumulation within the mitochondria could be deleterious
to mitochondrial function (Sorensen et al., 2016). Pt was
detected in both the nuclear (3.95 ppm) and mitochondrial
(1.97 ppm) fractions compared to VEH (p < 0.05, Figures 6A,B,
respectively). Of interest, there was ∼50% less Pt content
within the mitochondria subcellular fraction than in the
nuclear fraction. To assess the impact of OXA permeation on
mitochondrial capacity, we next investigated the content of the
mitochondrial enzyme, SDH in TA sections (Figure 6C). There
was a significant increase (∼20%) in the SDH content of OXA
treated mice compared to VEH (p < 0.005; Figure 6C), however
BGP-15 had no effect on this parameter.
OXA Treatment Does Not Induce PARP
Expression in Skeletal Muscle
PARP activation occurs secondary to DNA damage, and as
such, we next investigated whether OXA treatment could induce
PARP. Of particular interest was whether the PARP-inhibitor
BGP-15 could inhibit induction of PARP activity. As such we
quantified PARP1, PARP2, and total PARylation (marker of
PARP activity, Gibson and Kraus, 2012, Figure 7) in TA muscles.
Surprisingly there was no effect of OXA treatment on either
PARP1 or 2 expression or total PARylation in TA. To this extent,
there was no effect of BGP-15 on these parameters since PARP
was not activated.
BGP-15 Adjunct Treatment Improves
Mitochondrial Viability and Protects
against OXA-Induced Mitochondrial
Changes
mtROS are prevalent mediators of various muscle wasting
mechanisms, including atrophy and apoptosis, and their
production can be exacerbated if the mitochondria become
dysfunctional or damaged (Kirkinezos and Moraes, 2001; Lenaz
et al., 2002; Kujoth et al., 2005; Le Bras et al., 2005; Holzerová
and Prokisch, 2015). At the mitochondrial level, OXA treatment
induced a significant increase in mitochondrial density (p< 0.05,
Figure 8A) and superoxide production (p < 0.05, Figure 8B) in
FDB fibers, with OXAB treatment protecting against these effects.
Interestingly, BGP-15 significantly increased mitochondrial
viability 4-fold from OXA treated fibers (p < 0.005, Figure 8C)
and 2-fold from VEH (p = 0.073) with OXA treatment
alone showing a trend to decrease viability from VEH levels
(p= 0.077).
OXA Reduces Protein Synthesis Markers
To elucidate whether the reduction in lean mass observed with
OXA treatment corresponded with the activation of skeletal
muscle atrophy signaling pathways, a variety of atrophy-related
molecular signaling proteins were quantified via western blot.
Of note, OXA treatment induced a 28% reduction of total
p70S6K expression compared to VEH (p < 0.005, Figure 9B)
indicating a reduced potential for protein synthesis. This was
corroborated downstream by a drop in ribosomal protein S6
expression (rpS6, downstream transcription protein regulator,
p < 0.05, Figure 9C) and a trend for a reduction in protein
concentration within the TA (p = 0.081, Figure 9A). Of
note, OXA treatment reduced BAX expression (apoptosis
initiating protein, p < 0.05, Figure 9E) compared to VEH
suggesting a reduced propensity for apoptosis induction. BGP-
15 treatment protected against protein concentration reduction,
however, had no observable effect on markers of protein
synthesis.
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FIGURE 4 | OXA and BGP-15 treatment effect fiber size distribution in TA muscle. (A) Representative images of H&E stained TA and fiber size frequency
histogram (B) OXA treatment significantly increased the frequency of fibers in the 600-899µm2 and >4,900µm2 size bins whilst reducing the frequency of fibers in
the 1,500–1,799µm2 size bin. Significance: 8p < 0.0005 VEH compared to OXA and p < 0.05 VEH from OXAB; ‡p < 0.005 VEH and OXAB compared to OXA,
†p < 0.05 OXA and OXAB compared to VEH. n = 4.
DISCUSSION
In this study we demonstrate that OXA chemotherapy:
(1) significantly reduces body weight which is underpinned
by a decline in lean tissue and liver mass; (2) does not
impact voluntary exercise capacity, O2 consumption or energy
expenditure in mice; (3) shifts fiber size distribution to favor
smaller fibers in the TA whilst increasing collagen, neutral
lipid, and Ca2+ accumulation; (4) reduces FDB fiber diameter;
(5) penetrates the mitochondria and increases mitochondrial
population and superoxide (O−2 ) production in FDB fibers and
SDH content/capacity in TA; and (6) reduces molecular markers
of protein synthesis pathways with the tendency to reduce
intramuscular protein content. Importantly, our data highlights
a novel application for the pharmacological cytoprotectant, BGP-
15, which when administered with OXA (OXAB) protected
against the observed reductions in lean tissue mass and
FDB fiber diameter and TA protein content, mitochondrial
O−2 production and histopathological features of TA sections.
BGP-15 adjunct therapy also increased mitochondrial pool
viability and reduced the energy expenditure of mice during
inactivity.
Chemotherapeutic drugs are well described as toxic
antineoplastic agents capable of causing significant side
effects in healthy tissues (Davies and Doroshow, 1986; Sternberg
et al., 2001; Lu, 2005; Argilés et al., 2015). In skeletal muscle,
this correlates with sustained dysfunction resulting in fatigue
and wasting (Mantovani et al., 2003; Gilliam and St Clair,
2011; Gilliam et al., 2012; Gouspillou et al., 2015), with
wasting being traditionally attributed to an imbalance between
protein degradation and synthesis (Sandri, 2008). Since a
decline in muscle mass is negatively associated with patient
survivability, quality of life and chemotherapeutic treatment
options (Talvensaari et al., 1996; Oeffinger et al., 2006; van
Brussel et al., 2006; Ness et al., 2007, 2012; Scheede-Bergdahl
and Jagoe, 2013), methods to protect the skeletal muscle from
dysfunction and loss is of paramount importance. Here we have
investigated the effect of 2 weeks of OXA treatment in 6 week
old Balb/c mice and observed, as expected, a marked reduction
in body weight from D8 onwards (when compared to VEH,
Figure 1A). Once a cumulative dose of 9 mg/kg of OXA was
reached, mice ceased to accumulate body mass which was shown
to be independent of caloric intake (Figure 1B), hydration
index (Figure 2C) and energy expenditure (Figure 3B). Further
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FIGURE 5 | BGP-15 protects against OXA-induced increases in
intracellular Ca2+, collagen deposition and fat infiltration in TA muscle.
OXA treatment increased (A) intracellular Ca2+ content (B) fibrotic tissue and
collagen deposition and (C) fat infiltration with OXAB protecting against all
these parameters in TA muscles. A.U., Arbitrary units; ORO, Oil Red O.
Significance: *p < 0.05, **p < 0.005.
analysis of body composition elucidated that OXA treatment
depressed total lean tissue mass with a tendency for fat mass to
follow the same declination when indexed against absolute body
weight (Figures 2A–C). It is interesting to speculate that the loss
of lean mass (and tendency for the loss of fat mass) might be
strongly correlated with OXA-induced enteric neuropathy and
gastrointestinal dysfunction which has been reported previously
(Stojanovska et al., 2015; McQuade et al., 2016a) and which likely
limits the capacity for nutrient absorption in the small intestine.
Skeletal muscle mass is strongly associated with the nutritional
status of the organism (Jeejeebhoy et al., 1990; Mithal et al.,
2013; Moon, 2014), whereby in times of nutrient deprivation
(i.e., starvation), skeletal muscle protein synthesis pathways are
inhibited and degradation pathways are activated to liberate
nutritionals stores (particularly glucose and amino acids) for
key physiological functions (Thissen et al., 1994; Levine and
Kroemer, 2008). Our protein analyses, although a small snapshot
of a complex and dynamic system, suggests that OXA treatment
reduces p70s6K (Figure 9B) and rpS6 expression and has the
tendency to reduce intramuscular protein content, possibly via
inhibition of the master hypertrophy regulator, mTOR, which
is notably inhibited by nutrient deprivation in skeletal muscle
(Mammucari et al., 2008; Pasiakos et al., 2010; Zoncu et al., 2011;
Laplante and Sabatini, 2012). mTOR inhibition is also typically
accompanied by the induction of skeletal muscle degradative
pathways (Mammucari et al., 2008; Pasiakos et al., 2010). While
we show no effect of OXA on MURF1 (Figure 9F) or the
autophagy regulator p62 (Figure 9G), there are several other
pathways implicated in nutrient-deprivation related skeletal
muscle wasting that we have not investigated (such as TRAF6
Fan and Cook, 2004; Kumar et al., 2012; Paul et al., 2012) and
which may be causing the loss of lean mass observed in our
study.
Promisingly, adjunct BGP-15 therapy protected mice against
OXA-induced changes in lean tissue mass. We have shown that
BGP-15 can protect myenteric neurons against OXA-induced
insult to ameliorate gastrointestinal dysfunction (McQuade
et al., 2016b)—thus it is likely that BGP-15 promotes nutrient
absorption and the overall nutritional status, thus protecting the
muscle mass. Interestingly, we observed a marked reduction in
liver weight as a result of OXA treatment which is consistent
with glycogen depletion, however this effect was exacerbated
by BGP-15 treatment. The effect of BGP-15 on liver mass is
curious and could be a direct effect of drug metabolism that has
not been reported previously. BGP-15 adjunct therapy was also
observed to increase heart size to body weight ratio (Figure 2D).
While this could be indicative of cardiac hypertrophy, previous
studies have shown BGP-15 to be cardio-protective against heart
failure and inflammation (Szabados et al., 2000; Sarszegi et al.,
2012; Sapra et al., 2014). Indeed, our exercise and VO2 data
indicate no performance deficit following OXAB treatment, thus
the increased heart weight to body weight ratio observed appears
not to be detrimental to function.
Exercise therapy is an emerging treatment against
chemotherapy- and cachexia-driven skeletal muscle wasting
(Al-Majid and McCarthy, 2001; Smuder et al., 2011; Jarvela
et al., 2012; Kavazis et al., 2014; Bredahl et al., 2016). While
exercise before, during and after anti-cancer therapy is a field
of research that has gained traction in the recent years, there is
currently no established protocol that is prescribed in the clinic
to prevent and/or treat skeletal muscle atrophy during cancer
treatment (André et al., 2004; Alcindor and Beauger, 2011).
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FIGURE 6 | OXA penetrates the nuclear and mitochondrial fractions of TA muscle homogenates and increases succinate dehydrogenase (SDH)
content. (A) OXA penetrated the nuclear and (B) mitochondrial fractions as quantified by Pt detection (n = 3–4). (C) SDH staining was significantly increased with
OXA treatment but OXAB had no effect on this measure (n = 6–8). [Pt], Platinum concentration; SDH, SDH Succinate dehydrogenase; ppm, parts per million.
Significance: *p = <0.05, **p = <0.005, ***p = <0.0005.
For these reasons and in light of our observed reduction in
lean mass, investigations into exercise tolerability and capacity
were performed. Surprisingly, OXA treatment did not hinder
voluntary exercise participation in mice (Figures 3D–F), nor did
chemotherapy alter average exercise intensity (data not shown),
duration or distance (Figures 3D–F). Interestingly though,
behavioral analysis of the mice in relation to time budgeting of
activities of daily living revealed that OXA-treated mice engaged
in fewer long lounge periods (indicative of rest and sleep)
during the 24 h analysis period, which is contradictive to the
fatigue reported by chemotherapy-treated patients (Love et al.,
1989; Greene et al., 1993). Given we concomitantly observed
a strong trend (p = 0.057) for OXA-treated mice to interact
with the food hopper, our data suggest that these mice might
be waking more frequently to eat which is consistent with our
nutrient deprivation hypothesis. As with our body composition
data, BGP-15 protected against this OXA-induced behavioral
change.
It is reasonable to assume that exercise could be more
arduous for OXA treated mice due to the decline in lean tissue
mass, however, gas exchange analysis showed comparable RQ
and O2 consumption between VEH and OXA groups at all
levels of exercise intensity, and at rest. BGP-15 adjunct therapy,
however, reduced basal energy expenditure at rest (Figure 3B)
and increased mouse exercise performance (reduced time spent
on wheel compared to other groups Figures 3D,F with same
distance outcome Figure 3E) suggesting that BGP-15 has the
capacity to improve exercise efficiency, possibly due to improved
mitochondrial coupling (Conley et al., 2013). Indeed, enhanced
mitochondrial efficiency is a key adaptation during nutrient
deprivation to increase energy extraction frommacronutrients in
the form of ATP as opposed to heat (Weyer et al., 2000).While we
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FIGURE 7 | OXA and BGP-15 treatment does not alter PARP expression in mouse TA. No changes in (A) total PARylation (B) PARP1 or (C) PARP2 were
detected following OXA treatment. Adjunct treatment with the PARP inhibitor BGP-15 (OXAB) did not alter PARP expression. (D) Representative stainfree Western blot
images are digitally cut together to remove blots of other chemotherapies not presented in this manuscript, no other alteration was performed.
did not measure skeletal muscle uncoupling protein expression
or inducible uncoupling in our study (a noteworthy limitation),
our data suggests that BGP-15 might protect the skeletal muscle
from chemotherapy/nutrient-deprivation-induced wasting by
enhancing mitochondrial efficiency (Figure 8C).
In addition to mass, muscle quality is a major contributor to
the overall functional and reparative capacity of the muscle. To
this effect, a reduction in quality (i.e., increased intra- and inter-
muscle fat) irrespective of absolute mass would greatly impede
a patients’ ability to perform activities of daily living, ultimately
reducing independence and quality of life. Histological analysis
of TA muscles following OXA treatment highlighted features
consistent with myopathy including a significant accumulation
of both Ca2+ and neutral lipids within the TA architecture
(Figures 5A,C). Furthermore, markedly higher levels of collagen
deposition were identified in OXA-treated TA muscle. These
findings, taken together with the fact that hind limb muscle
weights were comparable to VEH following OXA treatment,
suggest that gross measurement of muscle weight was not
sensitive enough to detect changes in muscle mass, whereby
increased collagen and fat would contribute to muscle weight.
At the cross sectional level, OXA treatment shifted the fiber
size distribution to the left, in particular, reducing the number
of fibers within the 1,200–2,999µm2 fiber cross sectional area
range, whilst increasing the number of smaller fibers within the
300–1,199µm2 bin ranges (Figure 4B). While the mechanism
behind this fiber size distribution shift remains unclear, the
significant increase in fibers above 4,900µm2 in OXA treated
mice (21x greater compared to VEH) suggests that OXA
treatment induced pathological changes. Pseudohypertrophic
fibers are a pronounced feature of myopathy, in which healthy
fibers hypertrophy to compensate for the loss of strength induced
by muscle atrophy, wasting and/or replacement with non-
functional tissue (such as fat and connective tissue; Briguet
et al., 2004; Timpani et al., 2016). Importantly, BGP-15 adjunct
therapy ameliorated all of these OXA-induced pathologies
by protecting against Ca2+, lipid and collagen accumulation
and restoring a normal fiber distribution. These findings,
albeit novel in the chemotherapy/skeletal muscle arena, align
with the findings of a recent study by Salah et al. (2016)
who demonstrated that BGP-15 could protect against fibrotic
tissue and collagen accumulation within mechanically-ventilated
diaphragm muscle. They suggested that BGP-15’s efficacy was
mediated via membrane lipid therapy mechanisms (Salah et al.,
2016), an effect that has also been established in other myopathies
(Gehrig et al., 2012). Furthermore, BGP-15 has recently been
shown to improve certain myopathological aspects of DMD such
as collagen deposition (Kennedy et al., 2016), which is consistent
with our data.
Chemotherapy-induced oxidative stress has previously
been linked, albeit almost exclusively following anthracycline
treatment (Gilliam et al., 2012; Gouspillou et al., 2015), to
mitochondrial-mediated cell damage pathways within skeletal
muscle (Davies and Doroshow, 1986; Doroshow and Davies,
1986; Gilliam et al., 2012; Min et al., 2015). Since OXA, via
the Pt component of the molecule, adducts nDNA resulting
in DNA damage, impeded transcription/translation and cell
death (Raymond et al., 1998; André et al., 2004; Gourdier
et al., 2004; Alcindor and Beauger, 2011), we have previously
hypothesized that OXA could induce the same damage to
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FIGURE 8 | BGP-15 protects against OXA-induced mitochondrial superoxide production and fiber diameter loss and improves mitochondrial viability
in FDB fibers. OXA treatment induced (A) A 4-fold increase in mitochondrial density, with OXAB protecting against this increase. (B) OXAB protected against a 25%
increase in MitoSOX fluorescence induced by OXA treatment. (C) OXA treatment reduced mitochondrial viability while OXAB treatment protected against the effects of
OXA and improved viability 4-fold from VEH. Representative images of MitoSOX and MitoTracker stained FDB fibers (D,E). OXA treatment also induced a (F) 25%
reduction in FDB Fiber diameter with OXAB protecting against this reduction. FDB, Flexor Digitorum Longus; Mito, Mitochondria; SOX, Superoxide. Significance: *p <
0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001. Trend: #p = 0.073, ##p = 0.077. n = 4–6.
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FIGURE 9 | OXA treatment reduces protein synthesis and concentration within TA muscle. (A) OXA treatment showed a trend to reduce total protein
concentration, and reduced (B) total p70S6K and (C) total rpS6 when compared to VEH suggesting a suppression of protein synthesis. (D) Apoptosis initiation
marker total Bax was also supressed in TA muscle. Contrastingly no change in (E) total ubiquitin-proteasome marker MuRF1 or (F) autophagy marker p62 expression
was noted. (G) Western blot representative images are digitally cut together to remove blots of other chemotherapies not presented in this manuscript, no other
alteration was performed. Significance: *p < 0.05, **p < 0.005 Trend: #p = 0.081. n = 6–8.
mtDNA (Sorensen et al., 2016). To substantiate this, atomic
absorption spectrophotometry was utilized to detect Pt in
the subcellular mitochondrial fraction. Pertinently, we are
the first to show that OXA does in fact penetrate both the
skeletal muscle and the mitochondria, suggesting that OXA
could also be inducing Pt adducts into mtDNA (Figure 6B).
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The net effect of OXA treatment at the mitochondrial level
was increased succinate dehydrogenase (SDH) content within
the muscle, indicative of a greater mitochondrial oxidative
capacity. However, there was a trend for OXA (p = 0.07) to
reduce mitochondrial viability relative to VEH (Figure 8C),
highlighting that the innate response to oxidative stress and/or
mitochondrial toxicity is to increase the total pool to preserve
energy production capacity (Hsin-Chen et al., 2000) as indicated
by more intense SDH staining (Figure 6C) and mitochondrial
density (Figure 8C). Consistent with this finding, a marked
increase in mtROS production was detected in FDB fibers
following OXA treatment (Figure 8B) giving further support
to our theory that mitochondrial biogenesis could be increased
in order to accommodate oxidative stress and a dysfunctional
mitochondrial population (Hsin-Chen et al., 2000; Kujoth
et al., 2005; Stowe and Camara, 2009; Sorensen et al., 2016).
Remarkably, BGP-15 completely protected against the OXA-
induced increase in mtROS production and reduction in FDB
fiber diameter and intramuscular protein content, however,
this effect was independent from any modulation of protein
synthesis, atrophy, autophagy or apoptosis markers measured
in our study (Figure 9). Moreover, BGP-15 treatment was
shown to improve mitochondrial viability by 60% from OXA-
and 40% from VEH-treated groups (Figure 8C), which we
originally hypothesized would be due to molecular inhibition
of PARP and the restoration of mitochondrial substrates
(NADH) to the electron transport chain (NADH is a known
substrate of PARP) (Zhou et al., 2006). Unexpectedly though, we
were unable to detect any changes in PARP1, PARP2, or total
PARylation with OXA or OXAB treatment (Figure 7A–C). This
suggests in the first instance that OXA treatment at the dosage
administered (18 mg/kg cumulative dose) does not stimulate
PARP activity in skeletal muscle; and secondly that BGP-15
improved mitochondrial viability and normalized mtROS
production via an alternative mechanism. Since mtROS are key
mediators of muscle maintenance pathways (Powers et al., 2005,
2011, 2012; Min et al., 2011; Smuder et al., 2011), BGP-15’s
capacity to reduce mtROS could be key to its therapeutic
benefit. By limiting oxidative stress, BGP-15 likely affords
protection to the mitochondria from protein oxidation and
dysfunction, subsequently resulting in the observed increase in
both mitochondrial density and viability. While not a definitive
mechanism, we speculate that BGP-15 might achieve this by
enhancing mitochondrial coupling efficiency, which would
explain the lower resting energy expenditure observed in
mice and potentially reduce electron leak (and therefore ROS
production) concomitantly with proton leak. Certainly, our data
highlights the therapeutic potential of BGP-15 to protect against
the debilitating side-effects of OXA chemotherapy, at the whole
body, organ and mitochondrial levels.
LIMITATIONS
It should be noted, that the present study is limited in its
resemblance to the clinical setting in which only patients aﬄicted
with cancer are administered chemotherapy treatment. As such,
it does not take into consideration the complex interactions
between tumor-mediated cachexia and chemotherapy-driven
muscle wasting. Furthermore, the complexity of the pathways
underlying cachexia- and chemotherapy-driven wasting have
not been completely illuminated herein, with only a selection
of highly investigated protein markers of molecular atrophy
signaling being presented. At the organ level reductions in the
liver and heart mass were observed following OXA treatment
andwere exacerbated withOXAB treatment. Since blood samples
were not taken, we were unable to investigate markers of liver
damage (such as aspartate transaminase, alanine transaminase
and lactate dehydrogenase levels) which may have shed light
on the underlying mechanisms behind the observed decrease
in liver sizes with OXA and combination OXAB therapy.
Although investigations of lower limb muscle weights showed no
significant changes, this finding is limited in its interpretation
as the remaining upper limb and core muscles as well as
organs, such as the gastrointestinal tract and brain, were not
collected. Furthermore, fiber typing of the skeletal muscle was
not performed and this would be useful to determine whether the
OXA-induced increases in SDH and neutral lipid density within
TA sections were due to oxidative fiber type transitions. While we
are currently undertaking these investigations, previous studies
have shown that muscle mass loss induced by other pro-oxidant
chemotherapy drugs (specifically doxorubicin) is independent of
fiber type (Gilliam et al., 2009).
CONCLUSION
Chemotherapy treatment remains the foremost defense against
advanced neoplastic growth, however treatment often creates and
exacerbates considerable dysfunctions within the skeletal muscle
system, which endure well after chemotherapy treatment ceases.
This study has demonstrated that OXA-treatment reduces lean
mass, with the suppression of protein synthesis pathways a likely
contributing mechanism. Moreover, OXA treatment induces
various myopathic features including the accumulation of Ca2+,
neutral lipid, and collagen tissue within the muscle architecture,
a reduction in intramuscular protein content, a leftward shift in
the fiber size distribution and exacerbated mtROS production.
Importantly, we have highlighted the efficacy of BGP-15 therapy
to combat OXA-driven lean mass loss. For the first time we
have demonstrated that OXA can independently penetrate the
mitochondria, and is thus a likely contributor to these myopathic
features. We importantly show that BGP-15 adjunct therapy
either completely or partially protects the skeletal muscle against
these deleterious side effects. BGP-15 appears to modulate
the cytoprotective response to protect the mitochondria from
damage and enhance both pool density and viability, albeit not
via PARP inhibition. Although the precise mechanism of action
requires further elucidation, here we show a novel application for
the small molecule, BGP-15, in the protection of skeletal muscle
against platinum-based chemotherapy-induced myopathy and
wasting.
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